). Forme-phoshorylée-de-la-protéine-tauptau, 73 1.2.2.a, p.75

L. Autres-marqueurs-du and L. , 93 1.5.1. Peptide ?-amyloïde 1-40 (A? 40 ), Synucléine, p.102

.. Méthodologie-clinique, 109 1.1. Sélection des patients, p.112

S. Bakchine and M. Habert, Classification des d??mences??: aspects nosologiques, M??decine Nucl??aire, vol.31, issue.6, pp.278-293, 2007.
DOI : 10.1016/j.mednuc.2007.04.005

M. Paulin and F. Pasquier, Syndrome d??mentiel??: diagnostic et prise en charge, EMC - Trait?? de m??decine AKOS, vol.5, issue.2, pp.5-0745
DOI : 10.1016/S1634-6939(10)52283-X

J. Dartigues, C. Helmer, B. Dubois, C. Duyckaerts, B. Laurent et al., Alzheimer's disease : a public health problem : yes, but a priority, Rev Neurol (Paris), vol.158, pp.311-326, 2002.

. La-maladie-d, Alzheimer et les troubles apparentés. Rapport OPEPS n°2454, Juillet, 2005.

C. Gallez, La prise en charge de la maladie d'Alzheimer et des maladies apparentées, p.256, 2005.

A. Maltsev, S. Bystryak, and O. Galzitskaya, The role of ??-amyloid peptide in neurodegenerative diseases, Ageing Research Reviews, vol.10, issue.4
DOI : 10.1016/j.arr.2011.03.002

L. Guyant-marechal, D. Campion, and D. Hannequin, G??n??tique de la maladie d???Alzheimer??: formes autosomiques dominantes, Revue Neurologique, vol.165, issue.3, pp.223-231, 2009.
DOI : 10.1016/j.neurol.2008.10.019

S. Waring and R. Rosenberg, Genome-Wide Association Studies in Alzheimer Disease, Archives of Neurology, vol.65, issue.3, 2008.
DOI : 10.1001/archneur.65.3.329

L. Buée and A. Delacourte, Tauopathie et Maladie d'Alzheimer, un processus dégénératif à part entière, Psychol neuropsychiatr Vieil, vol.4, pp.261-73, 2006.

F. Lai and R. Williams, A Prospective Study of Alzheimer Disease in Down Syndrome, Archives of Neurology, vol.46, issue.8, pp.849-853, 1989.
DOI : 10.1001/archneur.1989.00520440031017

J. Moncaster, R. Pineda, R. Moir, S. Lu, M. Burton et al., Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. PloS One, e10659 -[15] Dartigues JF, 2010.

D. St-clair, D. Rennie, E. Slorach, J. Norrman, C. Yates et al., Apolipoprotein E epsilon 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers., Journal of Medical Genetics, vol.32, issue.8
DOI : 10.1136/jmg.32.8.642

E. Kabiri, A. Seddik, and S. , Prévention de la maladie d'Alzheimer, NPG, vol.6, issue.36, pp.12-22, 2006.

J. Kim, J. Basak, and D. Holtzman, The Role of Apoliprotein E in Alzheimer's Disease. Neuron, 2009.

T. Voisin, S. Lugardon, L. Balardy, B. Vellas, L. et al., Facteur de risque vasculaire et maladie d'Alzheimer. La revue de médecine interne, pp.288-291, 2003.
DOI : 10.1016/s0248-8663(03)80685-9

D. Dickstein, J. Walsh, H. Brautigam, S. Stockton, . Jr et al., Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, vol.19, issue.pt 3, pp.82-102, 2010.
DOI : 10.1007/BF03325209

V. Antoine and A. Rigaud, Maladie d'Alzheimer : prendre en compte les facteurs de risque et pathologies cardiovsculaires. La revue de médecine interne, pp.21-31, 2006.
DOI : 10.1016/j.revmed.2005.04.037

A. Ott, R. Stolk, A. Hofman, F. Van-harskamp, D. Grobbee et al., Association of diabetes mellitus and dementia: The Rotterdam Study, Diabetologia, vol.39, issue.11, pp.1392-1399, 1996.
DOI : 10.1007/s001250050588

A. Kontush and M. Chapman, HDL et maladies neurod??g??n??ratives, Médecine des maladies Métaboliques, 2009.
DOI : 10.1016/S1957-2557(09)70103-8

W. Xu, A. Atti, M. Gatz, N. Pedersen, B. Johansson et al., Midlife overweight and obesity increase late-life dementia risk: A population-based twin study, Neurology, vol.76, issue.18, pp.1568-74, 2011.
DOI : 10.1212/WNL.0b013e3182190d09

B. Ramesh, T. Rao, A. Prakasam, K. Sambamurti, and K. Rao, Neuronutrition and Alzheimer's Disease, Journal of Alzheimer's Disease, vol.19, issue.4, pp.1123-1139
DOI : 10.3233/JAD-2010-1312

C. Patterson, J. Feithghner, A. Garcia, R. Hsiung, G. Macknight et al., Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease, Canadian Medical Association Journal, vol.178, issue.5, pp.548-556, 2008.
DOI : 10.1503/cmaj.070796

L. Fratiglioni, H. Wang, K. Ericsson, M. Maytan, and B. Winblad, Influence of social network on occurrence of dementia: a community-based longitudinal study, The Lancet, vol.355, issue.9212, pp.1315-1324, 2000.
DOI : 10.1016/S0140-6736(00)02113-9

B. Dubois, H. Feldman, C. Jacova, J. Cummings, S. Dekosky et al., Revising the definition of Alzheimer's disease: a new lexicon, The Lancet Neurology, vol.9, issue.11, pp.1118-1145, 2010.
DOI : 10.1016/S1474-4422(10)70223-4

B. Dubois and Y. Agid, Plainte mnésique, trouble cognitif léger et maladie d'Alzheimer au stade prédémentiel, 2002.

N. Andreasen and K. Blennow, CSF biomarkers for mild cognitive impairment and early Alzheimer's disease, Clinical Neurology and Neurosurgery, vol.107, issue.3
DOI : 10.1016/j.clineuro.2004.10.011

E. Dionet, D. Frédérico, N. Foyatier-michel, S. Dirson, L. Cadet et al., Crit??res diagnostiques des troubles cognitifs l??gers dans une cohorte de 100??patients, Revue Neurologique, vol.165, issue.12, pp.1062-1070, 2009.
DOI : 10.1016/j.neurol.2009.03.011

O. Forlenza, B. Diniz, and W. Gattaz, Diagnosis and biomarkers of predementia in Alzheimer's disease, BMC Medicine, vol.23, issue.1, p.89, 2010.
DOI : 10.1146/annurev.publhealth.23.100901.140525

B. Dubois, H. Feldman, C. Jacova, D. Kosky, S. Barbeger-gateau et al., Research criteria for the diagnostis of Alzheimer's disease : revising the NINCDS-ADRDA criteria, Lancet Neurol, 2007.

F. Lopez-tourres, S. Lefebvre-chapiro, D. Fétéanu, and C. Trivalle, Soins palliatifs et maladie d'Alzheimer. La revue de médecine interne, pp.501-507, 2009.
DOI : 10.1016/j.revmed.2008.09.010

M. Fortin and P. Krolak-salmon, Maladie d'Alzheimer et maladies apparentées : vers un diagnostic plus précis et précoce. La revue de médecine interne, pp.86-853, 1931.
DOI : 10.1016/j.revmed.2010.08.006

D. Perl, Neuropathology of Alzheimer's Disease, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, vol.65, issue.1, pp.32-42, 2010.
DOI : 10.1212/WNL.53.5.902

A. Najlerahim and D. Bowen, Regional weight loss of the cerebral cortex and some subcortical nuclei in senile dementia of the Alzheimer type, Acta Neuropathologica, vol.103, issue.5, pp.509-521, 1988.
DOI : 10.1007/BF00687139

C. Yardin, Histopathologie de la maladie d'Alzheimer. Morphologie, pp.199-201, 2007.
DOI : 10.1016/j.morpho.2007.10.010

F. Checler and L. Buée, Données fondamentales sur les pathologies amyloïdes et Tau dans la maladie d'Alzheimer : quelles perspectives thérapeutiques? Annales Pharmaceutiques Françaises, pp.136-153, 2009.
DOI : 10.1016/j.pharma.2009.01.002

A. Delacourte, D. Campion, and P. Davous, Maladie d'Alzheimer. EMC Neurologie, 2007.

C. Duyckaerts, M. Panchal, B. Delatour, and M. Potier, Neuropathologie morphologique et mol??culaire de la maladie d???Alzheimer, Annales Pharmaceutiques Fran??aises, vol.67, issue.2, pp.127-135, 2009.
DOI : 10.1016/j.pharma.2009.01.001

E. Portelius, H. Zetterberg, J. Gobom, U. Andreasson, and K. Blennow, Targeted proteomics in Alzheimer???s disease: focus on amyloid-??, Expert Review of Proteomics, vol.78, issue.2, pp.225-237, 2008.
DOI : 10.1021/ac052263n

H. Englund, D. Gunnarson, M. Brundin, R. Hedlund, M. Kilander et al., Oligomerization Partially Explains the Lowering of A??42 in Alzheimer???s Disease Cerebrospinal Fluid, Neurodegenerative Diseases, vol.6, issue.4
DOI : 10.1159/000225376

D. Walsh and D. Selkoe, A? Oligomers ? a decade of discovery, Journal of Neurochemistry, vol.279, issue.5, pp.1172-84, 2007.
DOI : 10.1038/nn1630

N. Sergeant, A. Breteville, M. Hamdane, M. Caillet-boudin, P. Grognet et al., Biochemistry of Tau in Alzheimer???s disease and related neurological disorders, Expert Review of Proteomics, vol.6, issue.2, pp.207-231, 2008.
DOI : 10.1186/1471-2288-7-40

L. Buée and A. Delacourte, La maladie d'Alzheimer : une tauopathie parmi d'autres? Médecine, Sciences, vol.18, pp.727-763, 2002.

H. Braak and E. Braak, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathologica, vol.80, issue.4, pp.239-59, 1991.
DOI : 10.1007/978-3-642-70644-8_2

M. Spillantini and M. Goedert, Trends Neurosci, pp.428-461, 1998.

W. Mestsaars, J. Hauw, M. Van-welsem, and C. Duyckaerts, A grading system of Alzheimer disease lesions in neocortical areas, Neurobiology of Aging, vol.24, issue.4, pp.563-72, 2003.
DOI : 10.1016/S0197-4580(02)00134-3

C. Duyckaerts, M. Colle, F. Dessi, Y. Grignon, F. Piette et al., The progression of the lesions in Alzheimer disease: insights from a prospective clinicopathological study, J Neural Transm Supp, vol.53, pp.119-145, 1998.
DOI : 10.1007/978-3-7091-6467-9_10

R. Perrin, A. Fagan, and D. Holtzman, Multimodal techniques for diagnosis and prognosis of Alzheimer's disease, Nature, vol.289, issue.7266, pp.916-938, 2009.
DOI : 10.1016/S0002-9440(10)65185-1

G. Mckahnn, D. Drachman, M. Folstein, R. Katzman, D. Price et al., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, vol.34, issue.7, pp.939-983, 1984.
DOI : 10.1212/WNL.34.7.939

B. Dubois, Actualit??s de la maladie d???Alzheimer, Annales Pharmaceutiques Fran??aises, vol.67, issue.2, pp.116-142, 2009.
DOI : 10.1016/j.pharma.2008.11.004

G. Waldemar, B. Dubois, M. Emre, J. Georges, I. Mckeith et al., Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline, European Journal of Neurology, vol.46, issue.1, pp.1-26, 2007.
DOI : 10.1212/WNL.54.12.2205

L. Lechowski, B. Forette, and L. Teillet, Démarche diagnostique devant un syndrome démentiel. La revue de médecine interne, pp.363-75, 2004.
DOI : 10.1016/j.revmed.2003.07.003

M. Soto, E. Reynish, F. Nourashemi, and B. Vellas, Aspects cliniques de??la??maladie d'Alzheimer, La Presse M??dicale, vol.36, issue.10, p.10, 2007.
DOI : 10.1016/j.lpm.2007.04.024

V. L. Hahn-barma, évaluation neuropsychologique dans le cadre des démences neurodégénératives. Illustration avec la maladie d'Alzheimer. Pratiques psychologiques. 11, pp.307-324, 2005.

M. Boncoeur-martel, J. Monteil, and A. Maubon, Imagerie de la maladie d???Alzheimer??: IRM et imagerie fonctionnelle, Morphologie, vol.91, issue.295, pp.202-208, 2007.
DOI : 10.1016/j.morpho.2007.10.011

B. Desgranges, G. Kalpouzos, and F. Eustache, Imagerie c??r??brale du vieillissement normal : contraste avec la maladie d???Alzheimer, Revue Neurologique, vol.164, pp.102-107, 2008.
DOI : 10.1016/S0035-3787(08)73299-5

A. Forsberg, H. Engler, O. Almkvist, G. Blomquist, G. Hagman et al., PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiology of Aging, vol.29, issue.10, pp.1456-65, 2008.
DOI : 10.1016/j.neurobiolaging.2007.03.029

J. Hort, O. Brien, J. Gainotti, G. Pirttila, T. Popescu et al., EFNS guidelines for the diagnosis and management of Alzheimer???s disease, European Journal of Neurology, vol.65, issue.Suppl 3, pp.1236-1284, 2010.
DOI : 10.1212/01.wnl.0000167607.63000.38

P. Krolak-salmon, J. Seguin, A. Perret-liaudet, V. Desestret, A. Vighetto et al., Vers un diagnostic biologique de la maladie d'Alzheimer et des syndromes apparentés. La revue de médecine interne, pp.785-93, 2008.
DOI : 10.1016/j.revmed.2008.01.029

B. Michel, H. Becker, and J. Pelissier, Démence à corps de Lewy. EMC Neurologie, 2007.

J. De-la-torre, R. Kalaria, K. Nakajima, and K. Nagata, Alzheimer's disease : vascular etiology and pathology, Ann NY Acad Sci, vol.977, pp.1-526, 2002.

D. Neary, J. Snowden, L. Gustafson, U. Passant, D. Stuss et al., Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, vol.51, issue.6, pp.1546-54, 1998.
DOI : 10.1212/WNL.51.6.1546

V. Deramecourt, H. Leber, and F. Pasquier, Démences frontotemporales. EMC Neurologie, 2007.
DOI : 10.1016/s0246-0378(07)43820-9

J. Ghika, S. Joray, A. Brioshi, and R. Frackowiak, Atrophies focales. EMC Neurologie, 2010.
DOI : 10.1016/s0246-0378(10)26710-6

K. Wollen, Alzheimer's Disease : The Pros and Cons of Pharmaceutical, Nutritional, Botanical, and Stimulatory Therapies, with a Discussion of Treatment Strategies from the Perspective of Patients and Pratictionners. Alternative medicine review, pp.223-267, 2010.

D. Breihl, Le bon usage du médicament dans la prise en charge du patient Alzheimer Perspectives et recommandations. Le pharmacien hospitalier, Sept, vol.44, issue.1, pp.5-9, 2009.

D. Strooper, B. Vassar, R. Golde, and T. , The secretases: enzymes with therapeutic potential in Alzheimer disease, Nature Reviews Neurology, vol.21, issue.2, pp.99-107, 2010.
DOI : 10.1016/S0925-4439(00)00043-0

R. Motter, C. Vigo-pelfrey, D. Kholodenko, R. Barbour, K. Johnson-wood et al., Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease, Ann Neurol, 1995.

M. Vandermeeren, M. Mercken, E. Vanmechelen, J. Six, D. Van-de-voorde et al., Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme-Linked Immunosorbent Assay, Journal of Neurochemistry, vol.40, issue.5, pp.1828-1862, 1993.
DOI : 10.1002/ana.410220412

Y. Hu, S. He, X. Wang, Q. Duan, S. Khatoon et al., Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients, Neuroscience Letters, vol.320, issue.3, pp.156-60, 2002.
DOI : 10.1016/S0304-3940(02)00047-2

P. Formichi, C. Battisti, E. Radi, and A. Federico, Cerebrospinal fluid tau, A??, and phosphorylated tau protein for the diagnosis of Alzheimer's disease, Journal of Cellular Physiology, vol.72, issue.1, pp.39-46, 2006.
DOI : 10.1046/j.1471-4159.1999.0720741.x

S. Herukka, S. Helisalmi, M. Hallikainen, S. Tervo, H. Soininen et al., Tau and phosphorylated tau, APOE epsilon4 allele and MCI type in progressive MCI, Neurobiol Aging, 2007.

M. Vandermeeren, M. Mercken, E. Vanmechelen, J. Six, A. Van-de-voorde et al., Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme-Linked Immunosorbent Assay, Journal of Neurochemistry, vol.40, issue.5, pp.1828-1862, 1993.
DOI : 10.1002/ana.410220412

K. Blennow and E. Vanmechelen, CSF markers for pathogenic processes in Alzheimer???s disease: diagnostic implications and use in clinical neurochemistry, Brain Research Bulletin, vol.61, issue.3, pp.235-277, 2003.
DOI : 10.1016/S0361-9230(03)00086-8

H. Hampel, K. Blennow, L. Shaw, Y. Hoessler, H. Zetterberg et al., Total and phosphorylated tau protein as biological markers of Alzheimer???s disease, Experimental Gerontology, vol.45, issue.1, pp.30-40, 2010.
DOI : 10.1016/j.exger.2009.10.010

K. Blennow, E. Vanmechelen, and H. Hampel, CSF Total tau, A??42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease, Molecular Neurobiology, vol.24, issue.1-3, pp.87-97, 2001.
DOI : 10.1385/MN:24:1-3:087

K. Blennow, Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx, pp.213-238, 2004.

S. Schraen-maschke, C. Crinquette, S. Bombois, F. Pasquier, A. Delacourte et al., Les marqueurs biochimiques du LCR : un outil diagnostique de la maladie d???Alzheimer, NPG Neurologie - Psychiatrie - G??riatrie, vol.7, issue.37, pp.25-29, 2007.
DOI : 10.1016/S1627-4830(07)89957-0

K. Bürger-née-buch, F. Padberg, T. Nolde, S. Teipel, S. Stübner et al., Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls, Neuroscience Letters, vol.277, issue.1, pp.21-25, 1999.
DOI : 10.1016/S0304-3940(99)00845-9

T. Tapiola, I. Alafuzoff, S. Herukka, L. Parkkinen, P. Hartikainen et al., Cerebrospinal Fluid ??-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain, Archives of Neurology, vol.66, issue.3, pp.382-391, 2009.
DOI : 10.1001/archneurol.2008.596

A. Fagan, M. Mintun, A. Shah, P. Aldea, C. Roe et al., Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals : Implication for future clinical trials of Alzheimer's disease, EMBO Mol Med, vol.1, pp.8-9371, 2009.

P. Buchhave, K. Blennow, H. Zetterberg, E. Stomrud, E. Londos et al., Longitudinal Study of CSF Biomarkers in Patient with Alzheimer's Disease. PloS One, Jul, vol.174, issue.7, pp.6294-94, 2009.

H. Hampel, A. Goerntiz, and K. Buerger, Advances in the development of biomarkers for Alzheimer???s disease: from CSF total tau and A??1???42 proteins to phosphorylated tau protein, Brain Research Bulletin, vol.61, issue.3, pp.243-53, 2003.
DOI : 10.1016/S0361-9230(03)00087-X

A. Green, R. Harvey, E. Thompson, and M. Rossor, Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett, pp.133-138, 1999.

M. Bibl, B. Mollenhauer, S. Wolf, H. Esselmann, P. Lewczuk et al., Reduced CSF carboxyterminally truncated A?? peptides in frontotemporal lobe degenerations, Journal of Neural Transmission, vol.313, issue.11, pp.621-629, 2007.
DOI : 10.1212/WNL.54.10.1960

H. Bian, J. Van-swieten, S. Leight, L. Massimo, E. Wood et al., CSF biomarkers in frontotemporal lobar degeneration with known pathology, Neurology, vol.70, issue.Issue 19, Part 2, pp.1827-1845, 2008.
DOI : 10.1212/01.wnl.0000311445.21321.fc

M. Bibl, B. Mollenhauer, H. Esselmann, P. Lewczuk, C. Trenkwalder et al., CSF diagnosis of Alzheimer???s disease and dementia with Lewy bodies, Journal of Neural Transmission, vol.313, issue.11, pp.1771-1779, 2006.
DOI : 10.1212/WNL.56.4.576

B. Mollenhauer, M. Bibl, H. Esselmann, P. Steinacker, C. Trenkwalder et al., Tauopathies and synucleinopathies: Do cerebrospinal fluid ??-amyloid peptides reflect disease-specific pathogenesis?, Journal of Neural Transmission, vol.54, issue.Suppl 12, pp.919-946, 2007.
DOI : 10.1212/01.WNL.0000046581.81650.D0

J. Bahl, N. Heegaard, G. Falkenhorst, H. Laursen, H. Hogenhaven et al., The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease, Neurobiology of Aging, vol.30, issue.11, pp.1834-1875, 2009.
DOI : 10.1016/j.neurobiolaging.2008.01.013

B. Van-everbroeck, J. Boons, and P. Cras, Cerebrospinal fluid biomarkers in Creutzfeldt???Jakob disease, Clinical Neurology and Neurosurgery, vol.107, issue.5, pp.355-60, 2005.
DOI : 10.1016/j.clineuro.2004.12.002

C. Hesse, L. Rosengren, N. Andreasen, P. Davidsson, H. Vanderstichele et al., Transient increase un total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, 2001.

M. Boban, K. Grbié, M. Mladinov, P. Hof, C. Süssmair et al., Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia, Coll Antropol, vol.32, issue.1, pp.31-37, 2008.

A. Van-harten, M. Kester, P. Visser, M. Blankenstein, Y. Pijnenburg et al., Tau and p-tau as CSF biomarkers in dementia: a meta-analysis, Clinical Chemistry and Laboratory Medicine, vol.14, issue.3, pp.353-56, 2011.
DOI : 10.1258/acb.2009.008232

A. Gabelle, S. Roche, and S. Lehmann, Les marqueurs biologiques prot??iques du liquide c??phalorachidien??: caract??ristiques et implications cliniques dans les d??mences, Revue Neurologique, vol.165, issue.3, pp.213-235, 2009.
DOI : 10.1016/j.neurol.2008.05.004

H. Hampel, K. Buerger, R. Zinkowski, S. Teipel, A. Goernitz et al., Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease, Arch Gen Psychiatry, 2004.

E. Vanmechelen, H. Vanderstichele, P. Davidsson, E. Van-kerschaver, B. Van-der-perre et al., Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization, Neuroscience Letters, vol.285, issue.1, pp.49-52, 2000.
DOI : 10.1016/S0304-3940(00)01036-3

A. Mitchell, CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies, Journal of Neurology, Neurosurgery & Psychiatry, vol.80, issue.9, pp.966-75, 2009.
DOI : 10.1136/jnnp.2008.167791

N. Mattsson, K. Blennow, H. Zetterberg, and . Biomarkers, CSF Biomarkers, Annals of the New York Academy of Sciences, vol.7, issue.Suppl 3, pp.28-35, 2009.
DOI : 10.1212/01.WNL.0000156914.16988.56

H. Hampel, Y. Shen, D. Walsh, P. Aisen, P. Shaw et al., Biological markers of amyloid ??-related mechanisms in Alzheimer's disease, Experimental Neurology, vol.223, issue.2, pp.334-380, 2010.
DOI : 10.1016/j.expneurol.2009.09.024

P. Lewczuk, H. Esselmann, M. Otto, J. Maler, M. Henkel et al., Neurochemical diagnosis of Alzheimer???s dementia by CSF A??42, A??42/A??40 ratio and total tau, Neurobiology of Aging, vol.25, issue.3, pp.273-81, 2004.
DOI : 10.1016/S0197-4580(03)00086-1

C. Stenh, H. Englund, A. Lord, A. Johansson, C. Almeida et al., Amyloid-?? oligomers are inefficiently measured by enzyme-linked immunosorbent assay, Annals of Neurology, vol.1, issue.1, pp.147-50, 2005.
DOI : 10.1016/S0925-4439(00)00030-2

H. Fukumoto, T. Tokuda, T. Kasai, N. Ishigami, H. Hidaka et al., High-molecular-weight ??-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients, The FASEB Journal, vol.24, issue.8, pp.2716-2742, 2010.
DOI : 10.1001/archneurol.2008.565

W. Xia, T. Yang, G. Shankar, I. Smith, Y. Shen et al., A Specific Enzyme-Linked Immunosorbent Assay for Measuring ??-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer Disease, Archives of Neurology, vol.66, issue.2, pp.190-99, 2009.
DOI : 10.1001/archneurol.2008.565

A. Stefani, A. Martorana, S. Bernardini, M. Panella, F. Mercati et al., CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment, Journal of the Neurological Sciences, vol.251, issue.1-2, 2006.
DOI : 10.1016/j.jns.2006.09.014

K. Blennow and H. Hampel, CSF markers for incipient Alzheimer's disease. Lancet Neurol, 2003.

H. Zetterberg, K. Blennow, and E. Hanse, Amyloid ?? and APP as biomarkers for Alzheimer???s disease, Experimental Gerontology, vol.45, issue.1, pp.23-32, 2010.
DOI : 10.1016/j.exger.2009.08.002

J. Wiltfang, H. Esselmann, A. Smirnov, M. Bibl, L. Cepek et al., ?-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Annals of Neurology, vol.70, issue.2, pp.263-270, 2003.
DOI : 10.1136/jnnp.70.6.744

E. Mukaetova-ladinska, R. Monteith, and E. Perry, Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies, International Journal of Alzheimer's Disease, vol.7, issue.4, pp.2010-536
DOI : 10.1002/prca.200700081

M. Bibl, H. Esselmann, P. Lewczuk, C. Trenkwalder, M. Otto et al., Combined Analysis of CSF Tau, A?42, A?1?42% and A?1?40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia, Int J Alzheimers Dis, 2010.

M. Andersson, H. Zetterberg, L. Minthon, K. Blennow, and E. Londos, The cognitive profil and CSF biomarkers in dementia with Lewy bodies and Parkinson disease dementia, Int J Geriatr Psychiatry, vol.26100, issue.1, p.5, 2011.

E. Mulugeta, E. Londos, C. Ballard, G. Alves, H. Zetterberg et al., CSF amyloid ??38 as a novel diagnostic marker for dementia with Lewy bodies, Journal of Neurology, Neurosurgery & Psychiatry, vol.82, issue.2, pp.160-164, 2011.
DOI : 10.1136/jnnp.2009.199398

URL : https://hal.archives-ouvertes.fr/hal-00589971

Y. Pijnenburg, S. Schoonenboom, P. Mehta, S. Mehta, C. Mulder et al., Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration, Journal of Neurology, Neurosurgery & Psychiatry, vol.78, issue.7, pp.735-742, 2007.
DOI : 10.1136/jnnp.2006.105064

M. Bibl, B. Mollenhauer, P. Lewczuk, H. Esselmann, S. Wolf et al., Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-??<sub>38/40/42</sub> in Frontotemporal Dementias and Primary Progressive Aphasias, Dementia and Geriatric Cognitive Disorders, vol.31, issue.1, pp.37-44, 2011.
DOI : 10.1159/000322370

M. Otto, H. Esselmann, W. Schulz-schaeffer, M. Neumann, A. Schröter et al., Decreased ??-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Neurology, vol.54, issue.5, pp.1099-102, 2000.
DOI : 10.1212/WNL.54.5.1099

M. Sjögren, P. Davidsson, A. Wallin, A. Granérus, E. Grundström et al., Decreased CSF-??-Amyloid 42 in Alzheimer???s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of ??-Amyloid Induced by Disparate Mechanisms, Dementia and Geriatric Cognitive Disorders, vol.13, issue.2, pp.112-120, 2002.
DOI : 10.1159/000048642

P. Thompson and A. Lockhart, Monitoring the amyloid beta-peptide in vivo ??? caveat emptor, Drug Discovery Today, vol.14, issue.5-6, pp.5-6241, 2009.
DOI : 10.1016/j.drudis.2008.12.004

M. Sjögren, M. Gisslen, E. Vanmechelen, and K. Blennow, Low cerebrospinal fluid ??-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment, Neuroscience Letters, vol.314, issue.1-2, pp.33-39, 2001.
DOI : 10.1016/S0304-3940(01)02285-6

J. Wiltfang, H. Esselmann, M. Bibl, A. Smirnov, M. Otto et al., Highly conserved and disease-specific patterns of carboxyterminally truncated A?? peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation, Journal of Neurochemistry, vol.92, issue.3, pp.481-96, 2002.
DOI : 10.1073/pnas.92.20.9141

M. Smach, B. Charfeddine, B. Othman, L. Lammouchi, T. Dridi et al., Evaluation of Cerebrospinal Fluid Tau/Beta-Amyloid(42) Ratio as Diagnostic Markers for Alzheimer Disease, European Neurology, vol.62, issue.6, pp.349-55, 2009.
DOI : 10.1159/000241881

A. Maddalena, A. Papassotiropoulos, B. Müller-tillmanns, B. Yung, I. Hegi et al., Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42, Arch Neurol, vol.60, issue.9, pp.1202-1208, 2003.

M. Kester, L. Boelaarts, L. Bouwman, R. Vogels, E. Groot et al., Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic, Dementia and Geriatric Cognitive Disorders, vol.29, issue.6, pp.491-497, 2010.
DOI : 10.1159/000313534

C. Decarli, Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment, The Lancet Neurology, vol.2, issue.1, pp.15-21, 2003.
DOI : 10.1016/S1474-4422(03)00262-X

M. Shoji, Biomarkers of the Dementia, International Journal of Alzheimer's Disease, vol.9, issue.7, 2011.
DOI : 10.1007/s00401-008-0456-1

H. Hampel, S. Teipel, T. Fuchsberger, N. Andreasen, N. Wiltfang et al., Value of CSF ??-amyloid1???42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment, Molecular Psychiatry, vol.24, issue.7, pp.705-715, 2004.
DOI : 10.1016/S0197-4580(03)00002-2

L. Parnetti, A. Lanari, G. Silvestrelli, E. Saggese, and P. Reboldi, Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers, Mechanisms of Ageing and Development, vol.127, issue.2, pp.129-161, 2006.
DOI : 10.1016/j.mad.2005.09.022

O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow et al., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, The Lancet Neurology, vol.5, issue.3
DOI : 10.1016/S1474-4422(06)70355-6

N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti et al., CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment, JAMA, vol.302, issue.4, pp.385-93, 2009.
DOI : 10.1001/jama.2009.1064

P. Visser, F. Verhey, D. Knol, P. Scheltens, L. Wahlund et al., Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study, The Lancet Neurology, vol.8, issue.7, pp.619-646, 2009.
DOI : 10.1016/S1474-4422(09)70139-5

B. Snider, A. Fagan, C. Roe, A. Shah, E. Grant et al., Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type, Archives of Neurology, vol.66, issue.5, pp.638-683, 2009.
DOI : 10.1001/archneurol.2009.55

A. Fagan, C. Roe, C. Xiong, M. Mintun, J. Morris et al., Cerebrospinal Fluid tau/beta- Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults, Arch Neurol, 2007.

D. Gustafson, I. Skoog, L. Rosengren, H. Zetterberg, and K. Blennow, Cerebrospinal fluid beta-amyloid 1-42 concentration may predict coginitive decline in older women, J Neurol Neurosurg Psychiatry, 2007.

H. Hampel, G. Wilcock, S. Andrieu, P. Aisen, K. Blennow et al., Biomarkers for Alzheimer's disease therapeutic trials Pertinence des critères d'évaluation utilisés dans les essais cliniques sur la maladie d'Alzheimer, Prog Neurobiol Thérapie Mai, vol.64, issue.3, pp.139-182, 2009.

R. Bordet, J. Dartigues, B. Dubois, J. Goehrs, L. Vernoux et al., Alzheimer : biomarqueurs, nouveaux schémas d'études, phases précoces -[147 Biomarkers for the early stages of clinical development in Alzheimer's disease. Therapie, Table Ronde n°2 : Maladie d, pp.285-90, 2010.

C. Malaplate-armand, C. Desbene, T. Pillot, and J. Olivier, Diagnostic biologique de la maladie d???Alzheimer??: avanc??es, limites et perspectives, Revue Neurologique, vol.165, issue.6-7, pp.6-7511, 2009.
DOI : 10.1016/j.neurol.2008.10.015

L. Ol, J. Becker, W. Klunk, J. Saxton, R. Hamilton et al., Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades, Neurology, vol.55, issue.12, pp.1854-62, 2000.

S. Engelborghs, D. Vreese, K. Van-de-casteele, T. Vanderstichele, H. Van-everbroeck et al., Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia, Neurobiology of Aging, vol.29, issue.8, pp.1143-59, 2008.
DOI : 10.1016/j.neurobiolaging.2007.02.016

N. Schoonenboom, C. Mulder, H. Vanderstichele, V. Elk, E. Kok et al., Effects of Processing and Storage Conditions on Amyloid ?? (1-42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice, Clinical Chemistry, vol.51, issue.1, pp.189-95, 2005.
DOI : 10.1373/clinchem.2004.039735

M. Mattsson, U. Andreasson, S. Persson, H. Arai, D. Batish et al., The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimer Dement, 2011.

A. Gabelle, S. Roche, C. Gény, K. Bennys, P. Labauge et al., Correlations between soluble ??/?? forms of amyloid precursor protein and A??38, 40, and 42 in human cerebrospinal fluid, Brain Research, vol.1357, pp.175-83, 2010.
DOI : 10.1016/j.brainres.2010.08.022

J. Wiltfang, H. Esselmann, M. Bibl, M. Hüll, H. Hampel et al., Amyloid ? peptide ratio 42/40 but not A?42 correlates with phospho-Tau in patients with low- and high-CSF A?40 load, Journal of Neurochemistry, vol.6, issue.4, pp.1053-1062, 2007.
DOI : 10.1002/ana.10661

O. Hansson, H. Zetterberg, P. Buchhave, U. Andreasson, E. Londos et al., Prediction of Alzheimer???s Disease Using the CSF A??42/A??40 Ratio in Patients with Mild Cognitive Impairment, Dementia and Geriatric Cognitive Disorders, vol.163, issue.5, pp.316-336, 2007.
DOI : 10.1148/radiology.148.3.6878708

P. Mehta, T. Pirttilä, S. Mehta, E. Sersen, P. Aisen et al., Plasma and Cerebrospinal Fluid Levels of Amyloid ?? Proteins 1-40 and 1-42 in Alzheimer Disease, Archives of Neurology, vol.57, issue.1, pp.100-105, 2000.
DOI : 10.1001/archneur.57.1.100

M. Riverol and O. Lopez, Biomarkers in Alzheimer???s Disease, Frontiers in Neurology, vol.2, p.46, 2011.
DOI : 10.3389/fneur.2011.00046

N. Verwey, R. Veerhuis, H. Twaalfhoven, D. Wouters, J. Hoozemans et al., Quantification of amyloid-beta 40 in cerebrospinal fluid, Journal of Immunological Methods, vol.348, issue.1-2, pp.57-66, 2009.
DOI : 10.1016/j.jim.2009.06.011

M. Kester, P. Scheffer, M. Koel-simmelink, H. Twaalfhoven, N. Verwey et al., Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers, Neurobiology of Aging, vol.33, issue.8, 2011.
DOI : 10.1016/j.neurobiolaging.2011.05.013

E. Head, V. Pop, F. Sarsoza, R. Kayed, T. Beckett et al., Amyloid-?? Peptide and Oligomers in the Brain and Cerebrospinal Fluid of Aged Canines, Journal of Alzheimer's Disease, vol.20, issue.2, pp.637-683, 2010.
DOI : 10.3233/JAD-2010-1397

A. Anoop, P. Singh, R. Jacob, and S. Maji, CSF Biomarkers for Alzheimer's Disease Diagnosis, International Journal of Alzheimer's Disease, vol.34, issue.6, 2010.
DOI : 10.1016/S1474-4422(07)70178-3

R. Craig-schapiro, A. Fagan, and D. Holtzman, Biomarkers of Alzheimer's disease. Neurobiol Dis, 2009.

P. Spies, D. Slats, J. Sjögren, B. Kremer, F. Verhey et al., The Cerebrospinal Fluid Amyloid &#946;42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia, Current Alzheimer Research, vol.7, issue.5, pp.470-476, 2010.
DOI : 10.2174/156720510791383796

M. Brys, L. Glodzik, L. Mosconi, R. Switalski, D. Santi et al., Magnetic Resonance Imaging Improves Cerebrospinal Fluid Biomarkers in the Early Detection of Alzheimer's Disease, Journal of Alzheimer's Disease, vol.16, issue.2, pp.351-62, 2009.
DOI : 10.3233/JAD-2009-0968

M. Bibl, B. Mollenhauer, H. Esselmann, P. Lewczuk, H. Klafki et al., CSF amyloid-betapeptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia, Brain, 2006.

E. Portelius, H. Zetterberg, U. Andreasson, G. Brinkmalm, N. Andreasen et al., An Alzheimer's disease-specific ??-amyloid fragment signature in cerebrospinal fluid, Neuroscience Letters, vol.409, issue.3, pp.215-224, 2006.
DOI : 10.1016/j.neulet.2006.09.044

P. Crouch, S. Harding, A. White, J. Camakaris, A. Bush et al., Mechanisms of A?? mediated neurodegeneration in Alzheimer's disease, The International Journal of Biochemistry & Cell Biology, vol.40, issue.2, pp.181-98, 2008.
DOI : 10.1016/j.biocel.2007.07.013

D. Georganopoulou, L. Chang, J. Nam, C. Thaxton, E. Mufson et al., From The Cover: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease, Proceedings of the National Academy of Sciences, vol.53, issue.4, pp.2273-2279, 2005.
DOI : 10.1007/978-3-7091-6467-9_11

Z. Von-helmond, K. Heesom, and S. Love, Characterisation of two antibodies to oligomeric A?? and their use in ELISAs on human brain tissue homogenates, Journal of Neuroscience Methods, vol.176, issue.2, pp.206-218, 2009.
DOI : 10.1016/j.jneumeth.2008.09.002

Y. Kuo, M. Emmerling, C. Vigo-pelfrey, T. Kasunic, J. Kirkpatrick et al., Watersoluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains, J Biol Chem. Feb, vol.23271, issue.8, pp.4077-81, 1996.

J. Wang, D. Dickson, J. Trojanowski, and V. Lee, The Levels of Soluble versus Insoluble Brain A?? Distinguish Alzheimer's Disease from Normal and Pathologic Aging, Experimental Neurology, vol.158, issue.2, pp.328-365, 1999.
DOI : 10.1006/exnr.1999.7085

F. Cheng, G. Vivacqua, and Y. S. , The role of alpha-synuclein in neurotransmission and synaptic plasticity, Journal of Chemical Neuroanatomy, vol.42, issue.4, 2010.
DOI : 10.1016/j.jchemneu.2010.12.001

A. Ohrfelt, P. Grognet, N. Andreasen, A. Wallin, E. Vanmechelen et al., Cerebrospinal fluid ?synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett, Feb, vol.6450, issue.3, pp.332-337, 2009.

T. Tokuda, M. Qureshi, M. Ardah, S. Varghese, S. Shehab et al., Detection of elevated levels of ??-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, vol.75, issue.20, pp.1766-72, 2010.
DOI : 10.1212/WNL.0b013e3181fd613b

K. Kasuga, T. Tokutake, A. Ishikawa, T. Uchiyama, T. Tokuda et al., Differential levels of ??-synuclein, ??-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease, Journal of Neurology, Neurosurgery & Psychiatry, vol.81, issue.6, pp.608-618, 2010.
DOI : 10.1136/jnnp.2009.197483

M. Noguchi-shinohara, T. Tokuda, M. Yoshito, T. Kasai, K. Ono et al., CSF ??-synuclein levels in dementia with Lewy bodies and Alzheimer's disease, Brain Research, vol.1251, pp.1-6, 2009.
DOI : 10.1016/j.brainres.2008.11.055

C. Ballard and E. Jones, CSF ?-synuclein as a diagnostic biomarker for Parkinson disease and related demantias, Neurology Nov, vol.1675, issue.20, pp.1760-1761, 2010.

K. Johansen, L. White, S. Sando, and J. Aasly, Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies, Parkinsonism & Related Disorders, vol.16, issue.5, pp.307-322, 2010.
DOI : 10.1016/j.parkreldis.2010.02.015

O. Wirths and T. Bayer, ??-Synuclein, A?? and Alzheimer's disease, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.27, issue.1, pp.103-111, 2003.
DOI : 10.1016/S0278-5846(02)00339-1

C. Bate, S. Gentleman, and A. Williams, ??-synuclein induced synapse damage is enhanced by amyloid-??1-42, Molecular Neurodegeneration, vol.5, issue.1, pp.1-42
DOI : 10.1186/1750-1326-5-55

O. El-agnaf, S. Salem, A. Paleologou, M. Curran, M. Gibson et al., Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potentiel biomarker for Parkinson's disease

N. Andreasen, L. Minthon, P. Davidsson, E. Vanmechelen, H. Vanderstichele et al., Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice, Arch neurol, 2001.

K. Blennow, A. Wallin, and O. Häger, Low frequency of post-lumbar puncture headache in demented patients

E. Peskind, R. Riekse, J. Quinn, J. Kaye, C. Clark et al., Safety and Acceptability of the Research Lumbar Puncture, Alzheimer Disease & Associated Disorders, vol.19, issue.4, pp.220-225, 2005.
DOI : 10.1097/01.wad.0000194014.43575.fd

S. Donnadieu, Douleurs induites par les soins chez la personne âgée, Douleurs, vol.9, pp.22-27, 2008.
DOI : 10.1016/s1624-5687(08)70529-8

V. Giedraitis, J. Sundelöf, M. Irizarry, N. Garevik, B. Hyman et al., The normal equilibrum between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett, pp.127-158, 2007.

A. Sagare, R. Deane, R. Bell, B. Johnson, K. Hamm et al., Clearance of amyloid-?? by circulating lipoprotein receptors, Nature Medicine, vol.23, issue.9, pp.1029-1060, 2007.
DOI : 10.1016/S0002-9440(10)62995-1

M. Chen, N. Inestrosa, G. Ross, and H. Fernandez, Platelets Are the Primary Source of Amyloid ??-Peptide in Human Blood, Biochemical and Biophysical Research Communications, vol.213, issue.1, pp.96-103, 1995.
DOI : 10.1006/bbrc.1995.2103

Q. Li, S. Fuller, K. Beireuther, and C. Masters, The amyloid precursor protein of Alzheimer disease in human brain and blood, Journal of Leukocyte Biology, vol.66, issue.4, pp.567-74, 1999.
DOI : 10.1002/jlb.66.4.567

S. Freeman, S. Raju, B. Hyman, M. Frosch, and M. Irizarry, Plasma A?? Levels Do Not Reflect Brain A?? Levels, Journal of Neuropathology & Experimental Neurology, vol.148, issue.4, pp.264-71, 2007.
DOI : 10.1016/S1474-4422(06)70501-4

T. Kawarabayashi, L. Younkin, T. Saido, M. Shoji, K. Ashe et al., Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease, J Neurosci. Jan15, vol.21, issue.2, pp.372-81, 2001.

J. Sundelöf, V. Giedraitis, M. Irizarry, J. Sundström, E. Ingelsson et al., Plasma beta amyloid and the risk of Alzheimer disease and demantia in elderly men: a prospective, population-based cohort study

T. Seppälä, S. Herukka, T. Hänninen, S. Servo, M. Hallikainen et al., Plasma A??42 and A??40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study, Journal of Neurology, Neurosurgery & Psychiatry, vol.81, issue.10, pp.1123-1130, 2010.
DOI : 10.1136/jnnp.2010.205757

M. Van-oijen, A. Hofman, H. Soares, H. Koudstaal, and M. Breteler, Plasma A??1???40 and A??1???42 and the risk of dementia: a prospective case-cohort study, The Lancet Neurology, vol.5, issue.8, pp.655-60, 2006.
DOI : 10.1016/S1474-4422(06)70501-4

N. Graff-radford, J. Crook, J. Lucas, B. Boeve, D. Knopman et al., Association of Low Plasma A??42/A??40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease, Archives of Neurology, vol.64, issue.3, pp.354-62, 2007.
DOI : 10.1001/archneur.64.3.354

P. Modrego, I. Monleon, and M. Sarasa, The clinical significance of plasmatic amyloidAbeta40 peptide levels in Alzheimer's disease patients treated with galantamine. Am J Alzheimers Dis Other Dement, pp.286-90, 2008.

M. Irizarry, Biomarkers of Alzheimer disease in plasma, NeuroRX, vol.2, issue.2, pp.226-260, 2004.
DOI : 10.1038/nrd1130

P. Krolak-salmon, Quelle place pour les biomarqueurs dans le diagnostic de la maladie d'Alzheimer et des maladies apparentés, Psychol Neurol Psychiatr.Vieil, vol.8, issue.1, pp.25-31, 2010.

V. Solfrizzi, D. Introno, A. Colacicco, A. Capurso, C. Todarello et al., Circulating biomarkers of cognitive decline and dementia, Clinica Chimica Acta, vol.364, issue.1-2, pp.91-112, 2006.
DOI : 10.1016/j.cca.2005.06.015

B. Thies, E. Truschke, M. Morisson-bogorad, and R. Hodes, Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease, Neurobiol Aging, vol.20, issue.2, p.247, 1999.

M. Kanai, E. Matsubara, K. Isoe, K. Urakami, K. Nakashima et al., Longitudinal study of cerebrospinal fluid levels of tau, A?1-40, and A?1-42(43) in Alzheimer's disease: A study in Japan, Annals of Neurology, vol.37, issue.1, pp.17-26, 1998.
DOI : 10.1212/WNL.47.5.1113

K. Koopman, L. Bastard, N. Martin, J. Nagels, G. et al., Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P, Neurochemistry International, vol.55, issue.4, pp.214-222, 2009.
DOI : 10.1016/j.neuint.2009.02.017

B. Tau and . Ptau, A?1-42 dans le LCR : Propositions d'arbres décisionnels pour l'aide au diagnostic des démences et de la MA, Revue Neurologique, vol.165, pp.71-72, 2009.